<DOC>
	<DOC>NCT01931059</DOC>
	<brief_summary>To detect functional correlation changes in the brain with anti-psychotic drug administration as compared to placebo, and b.) to measure if these changes correlate with the plasma level of anti-psychotic, and c.) to evaluate if these changes correlate with drug induced symptoms and changes in cognitive function.</brief_summary>
	<brief_title>Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Risperidone</mesh_term>
	<criteria>Between 18 and 60 years of age Subject is competent to provide informed consent Mini Mental Status Exam is less than 28 Past or current history of any psychotic illness in the subject or in first degree family members Self report of illicit drug use (except marijuana) in the past. Use of marijuana during the last 3 month... Any use of antipsychotic in the past. Any neuroanatomical lesions on previous brain imaging Any use of D2 receptor blocking agent (such as antiemetics) in the last two weeks. Any use of any psychotropic medications (SSRI, mood stabilizers, benzodiazepines, stimulants) in the last month. MRI contraindications Any cardiovascular or cerebrovascular diseases or conditions that predispose patients to hypotension (eg. dehydration, hypovolemia, antihypertensive medication) Subjects with diabetes mellitus, metabolic syndrome, hepatic or renal impairment, seizure disorder and any neurological disorder QTc interval longer than 450 ms for male and 470 ms for female Subjects who used any medications in the last two weeks (to avoid any possible drugdrug interactions) Pregnancy Individuals who are illiterate and/or visually impaired</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Imaging</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Placebo</keyword>
	<keyword>antipsychotic</keyword>
</DOC>